A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control: Advantages of pathway-based discovery

被引:27
|
作者
Hellerstein, Marc K. [1 ,2 ,3 ]
机构
[1] Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA
[2] Univ Calif San Francisco, Dept Med, Div Endocrinol & Metab, San Francisco, CA 94110 USA
[3] KineMed Inc, Emeryville, CA 94608 USA
关键词
Drug discovery and development; Pathway-based discovery; Metabolic flux analysis; Exploiting complexity;
D O I
10.1016/j.ymben.2007.09.003
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Contemporary drug discovery and development (DDD) is dominated by a molecular target-based paradigm. Molecular targets that are potentially important in disease are physically characterized; chemical entities that interact with these targets are identified by ex vivo high-throughput screening assays, and optimized lead compounds enter testing as drugs. Contrary to highly publicized claims, the ascendance of this approach has in fact resulted in the lowest rate of new drug approvals in a generation. The primary explanation for low rates of new drugs is attrition, or the failure of candidates identified by molecular target-based methods to advance successfully through the DDD process. In this essay, I advance the thesis that this failure was predictable, based on modern principles of metabolic control that have emerged and been applied most forcefully in the field of metabolic engineering. These principles, such as the robustness of flux distributions, address connectivity relationships in complex metabolic networks and make it unlikely a priori that modulating most molecular targets will have predictable, beneficial functional outcomes. These same principles also suggest, however, that unexpected therapeutic actions will be common for agents that have any effect (i.e., that complexity can be exploited therapeutically). A potential operational solution (pathway-based DDD), based on observability rather than predictability, is described, focusing on emergent properties of key metabolic pathways in vivo. Recent examples of pathway-based DDD are described. In summary, the molecular target-based DDD paradigm is built on a naive and misleading model of biologic control and is not heuristically adequate for advancing the mission of modern therapeutics. New approaches that take account of and are built on principles described by metabolic engineers are needed for the next generation of DDD. (C) 2007 Published by Elsevier Inc.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 50 条
  • [1] Applying pathway-based drug discovery
    Westwick, JK
    GENETIC ENGINEERING NEWS, 2003, 23 (07): : 32 - +
  • [2] Target-based molecular modeling strategies for schistosomiasis drug discovery
    Ferreira, Leonardo G.
    Oliva, Glaucius
    Andricopulo, Adriano D.
    FUTURE MEDICINAL CHEMISTRY, 2015, 7 (06) : 753 - 764
  • [3] Unfinished business: target-based drug discovery
    Brown, David
    DRUG DISCOVERY TODAY, 2007, 12 (23-24) : 1007 - 1012
  • [4] Future target-based drug discovery for tuberculosis?
    Kana, Bavesh Davandra
    Karakousis, Petros C.
    Parish, Tanya
    Dick, Thomas
    TUBERCULOSIS, 2014, 94 (06) : 551 - 556
  • [5] Target-based drug discovery: is something wrong?
    Sams-Dodd, F
    DRUG DISCOVERY TODAY, 2005, 10 (02) : 139 - 147
  • [6] Drug Discovery for Neglected Diseases: Molecular Target-Based and Phenotypic Approaches
    Gilbert, Ian H.
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (20) : 7719 - 7726
  • [7] The utility of target-based discovery
    Croston, Glenn E.
    EXPERT OPINION ON DRUG DISCOVERY, 2017, 12 (05) : 427 - 429
  • [8] Target-based drug discovery for the development of novel antiinfectives
    Selzer, PM
    Brutsche, S
    Wiesner, P
    Schmid, P
    Müllner, H
    INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2000, 290 (02) : 191 - 201
  • [9] Navigating tuberculosis drug discovery with target-based screening
    Miller, Christopher H.
    O'Toole, Ronan F.
    EXPERT OPINION ON DRUG DISCOVERY, 2011, 6 (08) : 839 - 854
  • [10] Target-based drug discovery for malaria, leishmaniasis, and trypanosomiasis
    Werbovetz, KA
    CURRENT MEDICINAL CHEMISTRY, 2000, 7 (08) : 835 - 860